Understand the source comparison
The Functional Truth About LL-37 vs VIP
Here's the honest answer: there is no 'better' peptide between LL-37 and VIP. They don't compete for the same role. LL-37 is a frontline antimicrobial that operates at barrier surfaces where pathogens first encounter the immune system. VIP is a systemic regula
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Here's the honest answer: there is no 'better' peptide between LL-37 and VIP. They don't compete for the same role. LL-37 is a frontline antimicrobial that operates at barrier surfaces where pathogens first encounter the immune system. VIP is a systemic regulatory signal that tells immune cells when to stop producing inflammatory mediators. Asking which is better is like asking whether a neutrophil or a regulatory T cell is more important. The answer depends entirely on the phase of immune response you're studying.
- The confusion arises because both peptides have been marketed as 'immune-boosting' in wellness contexts, but their mechanisms are orthogonal. LL-37 boosts immunity by killing pathogens and recruiting effector cells. VIP 'boosts' immunity by preventing autoimmune damage and excessive inflammation. Which, mechanistically, means it suppresses certain immune responses. If your research question involves pathogen clearance, tissue repair, or innate immune activation, LL-37 is the peptide to use. If your question involves autoimmunity, neuroinflammation, or cytokine regulation, VIP is the correct choice. The only scenario where you're genuinely comparing them is when both are candidates for the same experimental arm. And in that case, the decision tree is straightforward: does your model involve microbial challenge? Use LL-37. Does it involve T cell-mediated pathology? Use VIP.